Intercept Pharmaceuticals Inc (ICPT) Forecasted to Earn FY2017 Earnings of ($13.17) Per Share

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) – Equities research analysts at Leerink Swann lowered their FY2017 earnings estimates for shares of Intercept Pharmaceuticals in a report released on Tuesday. Leerink Swann analyst J. Schwartz now anticipates that the biopharmaceutical company will post earnings per share of ($13.17) for the year, down from their prior estimate of ($13.14). Leerink Swann currently has a “Hold” rating and a $60.00 target price on the stock.

A number of other equities analysts have also recently weighed in on the stock. Oppenheimer reissued a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Thursday. Cantor Fitzgerald set a $58.00 price objective on shares of Intercept Pharmaceuticals and gave the company a “hold” rating in a research report on Wednesday. Wells Fargo & Co reissued a “market perform” rating and issued a $57.00 price objective (down from $62.00) on shares of Intercept Pharmaceuticals in a research report on Tuesday. Deutsche Bank began coverage on shares of Intercept Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $103.00 price objective for the company. Finally, Goldman Sachs Group cut shares of Intercept Pharmaceuticals from a “neutral” rating to a “sell” rating in a research report on Wednesday, February 7th. Five equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $132.38.

Intercept Pharmaceuticals (ICPT) opened at $56.02 on Thursday. The company has a debt-to-equity ratio of 3.15, a current ratio of 5.95 and a quick ratio of 5.95. The firm has a market cap of $1,340.70, a PE ratio of -3.79 and a beta of -2.13. Intercept Pharmaceuticals has a 12-month low of $51.05 and a 12-month high of $135.59.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.04). The firm had revenue of $37.69 million during the quarter, compared to analysts’ expectations of $39.01 million. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The business’s quarterly revenue was up 173.1% on a year-over-year basis. During the same period in the previous year, the company earned ($4.84) earnings per share.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. WFG Advisors LP lifted its holdings in Intercept Pharmaceuticals by 16.4% in the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 125 shares during the last quarter. Voya Investment Management LLC lifted its holdings in Intercept Pharmaceuticals by 4.7% in the second quarter. Voya Investment Management LLC now owns 6,994 shares of the biopharmaceutical company’s stock worth $847,000 after acquiring an additional 313 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in Intercept Pharmaceuticals by 23.3% in the second quarter. PNC Financial Services Group Inc. now owns 2,490 shares of the biopharmaceutical company’s stock worth $302,000 after acquiring an additional 470 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in Intercept Pharmaceuticals by 6.2% in the second quarter. Alliancebernstein L.P. now owns 9,459 shares of the biopharmaceutical company’s stock worth $1,145,000 after acquiring an additional 550 shares during the last quarter. Finally, California Public Employees Retirement System lifted its holdings in Intercept Pharmaceuticals by 2.3% in the second quarter. California Public Employees Retirement System now owns 31,000 shares of the biopharmaceutical company’s stock worth $3,753,000 after acquiring an additional 700 shares during the last quarter. 75.48% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/15/intercept-pharmaceuticals-inc-icpt-forecasted-to-earn-fy2017-earnings-of-13-17-per-share.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Earnings History and Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply